Change in the total number of shares and votes in Recipharm AB (publ)

As of 31 May 2016, the total number of shares in Recipharm AB (publ) (“Recipharm”) amounts to 52,774,552 shares, divided into 12,685,716 shares of series A, 39,588,836 shares of series B and 500,000 shares of series D. The total number of votes in Recipharm as of 31 May 2016 amounts to 166,945,996.

The number of shares and votes in Recipharm has increased as a result of the issue in kind of 3,159,572 shares of series B to the sellers of Kemwell AB, as announced by Recipharm on 23 May 2016.

For further information please visit www.recipharm.com or contact:

Thomas Eldered, CEO, +46 8 602 52 10

Björn Westberg, CFO, ir@recipharm.com, +46 8 602 46 20

This information is published in accordance with Chapter 4, Section 9 of the Swedish Financial Instruments Trading Act (SFS 1991:980). This information was submitted for publication on 31 May 2016, at 08:30 am CET.

About Recipharm

Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 3,500 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 5.0 billion and the Company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.  

For more information on Recipharm and our services, please visit www.recipharm.com 


Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52 00, Fax 46 8 81 87 03

www.recipharm.com

Tags:

About Us

About RecipharmRecipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 5,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 5.3 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm. For more information on Recipharm and our services, please visit www.recipharm.com

Subscribe

Documents & Links